focus -WSS

focus

author：entertainment 2025-09-30 00:49:47 - browse：552

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Yancopoulos of Regeneron works to expand Dupixent success

WSS

Steward Health Care expansion into Malta flopped

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

'Patient friction coefficient' can gauge a clinical trial's patient burden

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Woman returns to dialysis after doctors remove transplanted pig kidney

FDA's Pazdur wants cancer trials to range beyond China alone

explore

focus

focus

Drug repurposing or repositioning? The language matters

This gene therapy has record $4.25 million price. It's saved children.

Trump demands the U.S. pay no more for drugs than other countries … again

FDA's Pazdur wants cancer trials to range beyond China alone

Drug repurposing or repositioning? The language matters

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Continuity nursing helped my family in our darkest PICU moments

6 surprising facts about sugar

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

leisure time

With trial win, GSK could get blood cancer drug back on market

Yancopoulos of Regeneron works to expand Dupixent success

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Let's speed up science by embracing open access publishing

Biotech investment managers search for lucrative opportunities

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

hotspot

leisure time

entertainment

hotspot